Full Protocol Guide

BPC 157 10mg

A research-use BPC-157 protocol entry for safety review, product verification, and informed discussion of preclinical recovery literature.

BPC 157 10mg product vial
BPC 157 10mg vial Performance, Recovery & Muscle
ProductBPC 157 10mg
CategoryPerformance, Recovery & Muscle
FormatBPC 157 10mg vial
ReviewSource-linked guide

Contents

Use this guide as a structured review page. The same headings appear for every protocol so clients and the care team can scan the page consistently.

Important Note

This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.

  • Do not start, stop, combine, or change a protocol based only on website content.
  • Emergency symptoms require urgent medical care, not a website or routine follow-up message.

Quickstart Highlights

BPC-157 is a synthetic pentadecapeptide derived from a protein found in gastric juice, studied in preclinical models for tissue repair, recovery from soft-tissue injury, and protection of the gastrointestinal lining[3][4]. It is typically referenced as a daily subcutaneous or intramuscular injection dosed in micrograms, with the dry vial frozen and the mixed solution refrigerated. Human efficacy is unproven and it remains an unapproved research chemical — for research and educational use only.

  • Two options for the 10 mg vial: 3.0 mL bacteriostatic water → ~3,333 mcg/mL (gradual), or 2.0 mL → ~5,000 mcg/mL (advanced).
  • 300–500 mcg per day in standard use, 1–2 injections daily over a 4–8 week course; advanced schedules go higher.
  • At ~3,333 mcg/mL, 300 mcg ≈ 9 units; at ~5,000 mcg/mL, 500 mcg ≈ 10 units on a U-100 syringe.
  • Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within ~30 days.
  • Important: Read the Prep & Injection Guide first — it covers the preparation and safety basics that every protocol on this site assumes.

Dosing & Reconstitution Guide

Two reconstitution strategies with accurate daily dosing, step by step

Advanced / Aggressive Approach (2 mL = ~5,000 mcg/mL)
Phase / Week(s) Daily Dose Volume (U-100 units / mL)
Weeks 1–4 500 mcg (2× daily) ~10 units (0.10 mL) per injection
Weeks 5–8 750 mcg (2× daily) ~15 units (0.15 mL) per injection
  • Reconstitute: Add 3.0 mL bacteriostatic water to one 10 mg vial → final concentration: ~3,333 mcg/mL.
  • Typical daily range: 300–500 mcg once daily across a 4–8 week course.
  • Easy measuring: At ~3,333 mcg/mL, 300 mcg ≈ 9 units and 500 mcg ≈ 15 units on a U-100 insulin syringe. Note 9 units is just under 10 — a smaller-graduation syringe helps precision.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within ~30 days.
  • Frequency: one subcutaneous (or intramuscular) injection each day. A moderate 300–500 mcg daily dose is the most commonly referenced range for tissue-repair protocols[3]. These figures come from reference protocols, not from approved human dosing.
  • Reconstitute: Add 2.0 mL bacteriostatic water to one 10 mg vial → final concentration: ~5,000 mcg/mL.
  • Typical daily range: 500–750 mcg per injection, 2× daily for those referencing higher BPC-157 schedules.
  • Easy measuring: At ~5,000 mcg/mL, 500 mcg ≈ 10 units and 750 mcg ≈ 15 units per injection on a U-100 syringe.
  • Note: Each injection volume stays well within a single 100-unit insulin syringe.
  • Higher concentration: mixing to ~5,000 mcg/mL keeps injection volumes small even when dosing 500–750 mcg twice daily. Splitting the total across two injections is common in higher-dose reference schedules.

Reconstitution Steps

Draw the chosen volume of bacteriostatic water (3.0 mL for ~3,333 mcg/mL, or 2.0 mL for ~5,000 mcg/mL) into a sterile syringe.

  • Release it slowly against the vial’s inner wall to reduce foaming.
  • Swirl or roll gently until fully dissolved — don’t shake hard.
  • Note the mixing date and store at 2–8 °C (35.6–46.4 °F), shielded from light.
  • Both concentrations keep each dose within a single U-100 syringe. Pick the ~3,333 mcg/mL mix for moderate once-daily dosing, or the ~5,000 mcg/mL mix for compact volumes when injecting larger amounts twice daily.
  • Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Quantities below assume a 4–8 week course of daily injections at a moderate dose.

  • A single 10 mg vial covers the early weeks of a moderate daily protocol; higher or twice-daily dosing uses more.
  • 4 weeks (300–500 mcg/day): ~1–2 vials
  • 8 weeks (300–500 mcg/day): ~2–3 vials
  • Advanced (500–750 mcg, 2×/day): more vials needed
  • Per injection: 1 syringe
  • 8 weeks (once daily): ~56 syringes
  • 8 weeks (twice daily): ~112 syringes
  • Use 3.0 mL (gradual) or 2.0 mL (advanced) per 10 mg vial for reconstitution.
  • 4 weeks (1–2 vials): 3–6 mL → 1 bottle
  • 8 weeks (2–3 vials): 6–9 mL → 1 × 30 mL bottle
  • One for the vial stopper + one for the injection site each time.
  • Per injection: 2 swabs
  • 8 weeks (once daily): ~112 swabs → 1–2 boxes

Protocol Overview

A concise summary of daily use for tissue-repair and recovery support, drawn from commonly cited reference protocols.

  • ▪Goal: Support recovery and tissue-repair processes (preclinically reported for tendon, ligament, muscle and gut healing)[4].
  • ▪Schedule: Daily subcutaneous or intramuscular injections across a 4–8 week course.
  • ▪Dose Range: Typically 300–500 mcg/day; advanced references go up to ~750 mcg per injection, multiple times daily.
  • ▪Reconstitution: 3.0 mL water per 10 mg vial gives ~3,333 mcg/mL; 2.0 mL gives ~5,000 mcg/mL for compact higher doses.
  • ▪Storage: Keep the dry vial frozen at −20 °C (−4 °F); once mixed, refrigerate at 2–8 °C (35.6–46.4 °F) and use within ~30 days.

Dosing Protocol

A suggested daily injection approach based on common reference doses.

  • ▪Start: Begin around 300 mcg per day to gauge tolerability, then adjust as needed.
  • ▪Frequency: 1–2 injections per day; advanced schedules raise frequency rather than single-dose size.
  • ▪Maximum: Up to ~750 mcg per injection, multiple times daily, per advanced reference protocols.
  • ▪Cycle Length: Typically 4–8 weeks; some references extend to ~12 weeks.
  • ▪Timing: Space injections evenly through the day and keep the schedule consistent.

Storage Instructions

Correct storage is what preserves the peptide’s stability and potency.

  • ▪Lyophilized: Hold the dry vial frozen at −20 °C (−4 °F) until mixing; shield from moisture and light[11].
  • ▪Reconstituted: Chill at 2–8 °C (35.6–46.4 °F) as soon as it’s mixed and use within ~30 days[11].
  • ▪Handling: Let frozen vials warm to room temperature before opening so condensation won’t form; keep the solution clear of heat and direct light.
  • ▪Freeze–thaw: Avoid repeated freeze–thaw cycles, which degrade the peptide[12].

Important Notes

Practical points that keep daily administration safe and consistent.

  • ▪Daily consistency: Space injections evenly and keep to a steady schedule for the whole protocol.
  • ▪Sterile technique: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward[14].
  • ▪Site rotation: Move injection sites (abdomen, thighs, upper arms), keeping each at least 1 inch from the last to limit irritation[15].
  • ▪Higher-frequency dosing: For advanced schedules, split the daily total across two or more injections rather than one large volume.
  • ▪Side-effect monitoring: Watch for injection-site discomfort, headache or nausea; consult a professional if concerns arise, and consider cycling off after ~8 weeks.

How This Works

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a 15-amino-acid sequence derived from a protein found in gastric juice[3]. Nearly all of the evidence behind it comes from animal and in-vitro (preclinical) studies, not from completed human efficacy trials.

  • In those preclinical models it has been reported to promote angiogenesis — the growth of new blood vessels — through the VEGFR2–Akt–eNOS / nitric-oxide pathway, which may help explain its observed effects on healing[1][4].
  • Animal research has also described accelerated repair of tendon, ligament, muscle, bone and gut tissue, alongside cytoprotective and anti-inflammatory activity — particularly protection of the gastrointestinal lining[2][4].
  • Important caveat: human efficacy is unproven. The evidence base is overwhelmingly preclinical, and there are no completed, published Phase 2 or 3 human efficacy trials — only early-stage safety work[9]. Reported mechanisms should be read as hypotheses from laboratory and animal data.
  • BPC-157 is not an approved medicine. It is an unapproved research chemical presented here for research and educational purposes only and is not approved for general human use.

Lifestyle Factors

Habits that may support recovery alongside the protocol.

  • ▪Nutrition: Eat a balanced, protein-forward diet to give tissue repair the building blocks it needs.
  • ▪Activity & rest: Combine appropriate movement with adequate rest so healing tissue can recover.
  • ▪Hydration: Keep fluids up across the protocol.
  • ▪Sleep & stress: Aim for solid sleep and manage stress, both of which support recovery.

Potential Benefits & Side Effects

What preclinical research and anecdotal reports describe; human evidence is limited and individual results vary.

  • ▪Tissue repair (preclinical): Animal studies report faster tendon, ligament, muscle and bone healing[4].
  • ▪GI protection (preclinical): Reported cytoprotective effects on the gastrointestinal lining in animal models[2].
  • ▪Anti-inflammatory signalling: Preclinical anti-inflammatory and angiogenic activity has been described[1].
  • ▪Note on humans: These benefits are not established in humans — no completed Phase 2/3 efficacy trials exist.
  • ▪Injection-site reactions: Discomfort, redness or soreness at the site can occur; rotating sites helps.
  • ▪Other reported effects: Headache and nausea have been noted anecdotally.
  • ▪Unknown long-term profile: Long-term human safety data is limited; caution and monitoring are advised.

Injection Technique

Subcutaneous (or intramuscular) injection technique, following established clinical practice and CDC guidance[13][14].

  • ▪Wash your hands well with soap and water[14].
  • ▪Wipe the vial stopper with an alcohol swab and let it air-dry.
  • ▪Pick a site (abdomen, thigh, or upper arm) and wipe it with a fresh alcohol swab, letting it dry fully[13].
  • ▪Carefully draw the intended dose, then check for air bubbles and push any out.
  • ▪Pinch about a 1-inch fold of skin between thumb and forefinger[15].
  • ▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[13][14].
  • ▪Skip aspiration for subcutaneous shots — it isn’t needed and can add discomfort[13].
  • ▪Press the plunger slowly and steadily until it’s fully down.
  • ▪Pull the needle straight out and, if needed, press lightly with clean gauze.
  • ▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle[14].
  • ▪Put the reconstituted vial back in the fridge right away.
  • ▪Rotate the site with each injection (at least 1 inch over) to prevent irritation[15].
  • ▪Watch the site for excess redness, swelling, or signs of infection.

References

Reference-derived details for BPC 157 10mg.

  • BPC-157 (10mg Vial) Dosage Protocol Open source
  • 1 Journal of Pharmacological Sciences Klicek R et al. — BPC-157 modulates the NO-system and promotes healing (rat models of injury and fistula). View Source ↗ Open source
  • 2 World Journal of Gastroenterology (PMC) Sikiric P et al. — Pentadecapeptide BPC-157: from the GI tract to whole-body cytoprotection and healing. View Source ↗ Open source
  • 3 Current Pharmaceutical Design (PMC) Sikiric P et al. — Stable gastric pentadecapeptide BPC-157 in the treatment of wound healing and tissue repair. View Source ↗ Open source
  • 4 Life Sciences Seiwerth S et al. — BPC-157 and standard angiogenic growth factors: gastrointestinal tract healing and beyond. View Source ↗ Open source
  • 5 Journal of Orthopaedic Research Chang CH et al. — BPC-157 promotes tendon-to-bone healing in a rat rotator-cuff model. View Source ↗ Open source
  • 6 HSS Journal (PubMed) Vasireddi N et al. — Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review (2025). View Source ↗ Open source
  • 7 Pharmaceuticals (MDPI) Józwiak M et al. — Multifunctionality and possible medical application of BPC-157: literature and patent review (2025). View Source ↗ Open source
  • 8 ClinicalTrials.gov NCT02637284 — PCO-02: Phase I safety and pharmacokinetics trial of oral BPC-157 (early-stage human study). View Source ↗ Open source
  • 9 Journal of Dental Anesthesia and Pain Medicine Review of BPC-157 pharmacology and reported regenerative effects. View Source ↗ Open source
  • 10 PubMed Central (PMC) BPC-157 collagen-regeneration and wound-healing efficacy data (preclinical). View Source ↗ Open source
  • 11 GenScript Peptide storage and handling guidelines (lyophilized and reconstituted peptides). View Source ↗ Open source
  • 12 Bachem Handling and storage guidelines for peptides (stability and freeze–thaw cycles). View Source ↗ Open source
  • 13 Centers for Disease Control and Prevention (CDC) Vaccine administration: subcutaneous injection technique, angle and site guidance (no aspiration). View Source ↗ Open source
  • 14 WHO (NCBI Bookshelf) Guideline on safety-engineered syringes and aseptic technique for IM, ID and SC injections (2016). View Source ↗ Open source
  • 15 Pharmacologic Considerations of the Subcutaneous Route (PMC) Subcutaneous injection technique and site rotation to prevent lipohypertrophy. View Source ↗ Open source
  • 16 Prime Lab Peptides BPC-157 (10 mg) product page — quality documentation and certificates of analysis. View Source ↗ Open source